Podcasts about Biotronik

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Todd Langevin, president of BIOTRONIK Neuro, a familiar name in medical devices with a new approach to alleviating pain through spinal cord stimulation. Langevin, who has spent his career in neuro devices, gives his assessment of the field today, explaining how it's exceeded his early expectations. Just before that Tom talks with Joe Mullings of The Mullings Group and Surgical Robotics Expert Steve Bell about the state of the surgical robotics industry. The trio will talk about current leaders, emerging powers, and how a shift toward cardiac surgeons could change the playing field completely. But to start, MassDevice Editor Chris Newmarker joins Tom for the Newmarker's Newsmakers, the leading stories from the pages of MassDevice. This week's newsmakers include Tariffs, Medtronic, Surgical Robotics, Stryker, and BCI company Paradromics. Thank you for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

William Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by Wendy Tzou, MD, FHRS, University of Colorado Anschutz Medical Campus, and Arif Elvan, MD, PhD, Klinikum Braunschweig, to discuss a partial delineation of targets for ablation of ventricular tachycardia (VT) during a stable rhythm is likely responsible for a suboptimal success rate. The abnormal low-voltage near-field functional components may be hidden within the high-amplitude far-field signal. https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.jacep.2024.04.023 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): A.  Elvan: Honoraria/Speaking/Consulting: Abbott Medical  W. Tzou: Honoraria/Speaking/Consulting/Teaching: Medtronic, Biotronik, Mediasphere Medical, Biosense Webster, Inc., American Heart Association, Abbott, Boston Scientific, Membership on Advisory Committees: Medtronic, Inc., Biosense Webster, Inc., Kardium, BioTelemetry, Inc., Research: Abbott Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode92

Dr. Jason T. Jacobson, MD, FHRS, Westchester Medical Center, New York Medical College is joined by Melissa Robinson, MD, FHRS, Providence Heart Institute of Montana, and Dr. Sei Iwai, MD, FHRS, Westchester Medical Center, New York Medical College to discuss: BACKGROUND Factors determining hemodynamic stability during human ventricular tachycardia (VT) are incompletely understood. OBJECTIVES This study aimed to characterize sinus rate (SR) responses during monomorphic VT in association with hemodynamic stability and prospectively assess the effects of vagolytic therapy on VT tolerance. METHODS This is a retrospective analysis of patients undergoing scar-related VT ablation. Vasovagal responses were evaluated by analyzing sinus cycle length before VT induction and during VT. SR responses were classified into 3 groups: increasing ($5 beats/min, sympathetic), decreasing ($5 beats/min, vagal), and unchanged, with the latter 2 categorized as inappropriate SR. In a prospective cohort (n . 30) that exhibited a failure to increase SR, atropine was administered to improve hemodynamic tolerance to VT. RESULTS In 150 patients, 261 VT episodes were analyzed (29% untolerated, 71% tolerated) with a median VT duration of 1.6 minutes. A total of 52% of VT episodes were associated with a sympathetic response, 31% had unchanged SR, and 17% of VTs exhibited a vagal response. A significantly higher prevalence of inappropriate SR responses was observed during untolerated VT (sustained VT requiring cardioversion within 150 seconds) compared with tolerated VT (84% vs 34%; P < 0.001). Untolerated VT was significantly different between groups: 9% (sympathetic), 82% (vagal), and 32% (unchanged) (P < 0.001). Atropine administration improved hemodynamic tolerance to VT by 70%. CONCLUSIONS Nearly one-half of VT episodes are associated with failure to augment SR, indicative of an underrecognized pathophysiological vasovagal response to VT. Inappropriate SR responses were more predictive of hemodynamic instability than VT rate and ejection fraction. Vagolytic therapy may be a novel method to augment blood pressure during VT.   https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacc.2023.06.033 Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting: Zoll Medical, Abbott Medical, Vektor Medical, Stocks, Privately Held: Atlas 5D, Research: CardioFocus, Inc.   Contributor Disclosure(s): M. Robinson: Honoraria/Speaking/Consulting: Biosense Webster, Inc., Boston Scientific, Abbott, Membership on Advisory Committees: Medtronic Inc. S. Iwai: Honoraria/Speaking/Consulting: Alta Thera Pharmaceuticals, Biotronik

Sam Jones Company, LLC v. Biotronik, Inc.

141: Bernadette Christine Ritscherle ist Chief of Staff im Gesundheitssektor und leitet das CEO Office bei BIOTRONIK. Zuvor war sie in ähnlichen strategischen Positionen im Startup-Umfeld aktiv. Ihre berufliche Laufbahn begann Bernadette 2011 im Konsumgüter- und Healthcare Marketing bei Reckitt Benckiser und anschließend als Unternehmensberaterin bei Roland Berger. Bernadette hat eine Leidenschaft für Transformationsprozesse, Healthcare Trends, lebenslanges Lernen und Persönlichkeitsentwicklung. Chris, 33 Jahre alt, ist ein selbstständiger Finance Transformation Berater. Zuvor arbeitete er als Chief of Staff und gründete das Chief of Staff Netzwerk, das mittlerweile über 170 Mitglieder aus Europa zählt. Mit seiner umfassenden Erfahrung und seinem tiefen Verständnis für Finanztransformationen unterstützt er Unternehmen dabei, ihre finanziellen Abläufe zu optimieren und zu modernisieren. Chris ist weiterhin mit vielen Chiefs of Staff im Austausch und verfügt dadurch über ein breites Wissen und aktuelle Einblicke in die Branche. Links Folge als Video anschauen: https://youtu.be/pxzqCSf5F8g Diana auf LinkedIn: https://www.linkedin.com/in/diana-brandl/ The Future Assistant Newsletter: https://the-socialista-projects.com/#newsletter Zertifizierter Lehrgang zum Chief of Staff der Haufe Akademie in Kooperation mit der Hochschule der Wirtschaft für Management, Mannheim: https://www.haufe-akademie.de/36524 Politicwise Podcast: https://www.politicwise.org/s/podcast Fast & Curious: https://fastandcurious.podigee.io/ Tim Ferriss: https://tim.blog/podcast/ Matt Mochary: https://docs.google.com/document/d/1ZJZbv4J6FZ8Dnb0JuMhJxTnwl-dwqx5xl0s65DE3wO8/edit Huberman Lab Podcast: https://open.spotify.com/show/79CkJF3UJTHFV8Dse3Oy0P?si=ebf0970130434686 HBR: https://hbr.org/subscriptions EDX Learnign Platform: https://www.edx.org/ Falls sich jemand mit Chris austauschen will: https://www.mentoring-club.com/the-mentors/christopher-sorg Vernetzt euch mit den beiden: https://www.linkedin.com/in/bernadette-christine-ritscherle-39a51125/ https://www.linkedin.com/in/christophersorg/   Podcast auf YouTube: https://www.youtube.com/@the-socialista-projects Podcast auf Spotify: https://open.spotify.com/show/3qBSDjTfYOG2x6qos7dKkS Podcast auf Apple Podcast: https://podcasts.apple.com/de/podcast/the-future-assistant/id1493106661

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Microplastics and nanoplastics in atheromas and cardiovascular events Leadless pacemakers Snapshots Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Emanuele Barbato, Haran Burri Want to watch that episode? Go to: https://esc365.escardio.org/event/1148   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.    Declarations of interests  Stephan Achenbach, Emanuele Barbato, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Deepthy Varghese, MSN, ACNP, FNP, of Northside Hospital, is joined by Dr. Mikhael F. El-Chami, MD, FHRS of Emory University, School of Medicine, and Dr. Rohit Mehta, MD, FHRS, with Advocate Health to discuss the study evaluated the preclinical performance and safety of retrieving chronically implanted dual-chamber leadless pacemakers (LPs). A total of 18 LPs were implanted in 9 ovine subjects, and after approximately 2 years, all LPs were successfully retrieved using a dedicated transvenous retrieval catheter. The retrieval procedure duration ranged from 2.5 to 36.4 minutes. Postretrieval analysis showed minimal tissue disruption at implant sites, and no significant device-related complications or injuries were observed. The study concludes that the retrieval of helix-fixation dual-chamber LP systems was safe and effective, paving the way for future clinical studies on LP retrieval. https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCEP.123.012232 Host Disclosure(s): D. Varghese: No relevant financial relationships with ineligible companies to disclose. Contributor Disclosure(s): M. El-Chami: Honoraria, Speaking, and Consulting: Biosense Webster, Inc., Medtronic  R. Mehta: Honoraria/Speaking/Consulting: Medtronic, Biotronik, Stock Options, Privately Held: Huxley Biomedical, S4 Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode52

Deepthy Varghese, MSN, ACNP, FNP, of Northside Hospital, is joined by guests Sandeep K. Goyal, MD, FHRS, Piedmont Heart Institute, and Andrea M. Russo, MD, FHRS, Cooper University Hospital. to discuss the article explores that development and validation of the HARMS2-AF score, a novel lifestyle risk assessment tool for identifying atrial fibrillation (AF) risk in the general population. Using data from the UK Biobank and Framingham Heart Study, the score, derived through Cox proportional hazards regression, includes variables like hypertension, age, body mass index, sex, sleep apnea, smoking, and alcohol. Physical inactivity and diabetes were not significant predictors. The score demonstrated effective predictive performance in both cohorts, outperforming existing models like Framingham-AF and ARIC, and comparable to CHARGE-AF. In conclusion, the HARMS2-AF score is a valuable tool for lifestyle-related AF risk identification, aiding in population screening and potential early intervention. https://www.hrsonline.org/education/TheLead https://academic.oup.com/eurheartj/article/44/36/3443/7205602 Host Disclosure(s): D. Varghese: No relevant financial relationships with ineligible companies to disclose. Contributor Disclosure(s): A. Russo: Honoraria, Speaking, and Consulting: Pacemate, AtriCure, Inc., Bayer Healthcare Pharmaceuticals, Sanofi, Medtronic, Biosense Webster, Inc., Biotronik, Abbott Medical, Boston Scientific, BMS/PFizer Alliance, Royalty Income: UpToDate, Inc., Research: Medtronic, Boston Scientific, Fellowship Support: Medtronic, Board Membership: ABIM.  S. Goyal: Honoraria, Speaking, and Consulting: Biosense Webster, Inc., Medtronic This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode50

So far, in the podcast, I have been interviewing key opinion leaders from academia and clinical practice, and sometimes individual patients that graciously shared their insights after undergoing DBS. However, beyond patients and clinicians, there is a third component necessary for DBS to be successful, which are our partners in the industry. Without great industry leadership, it is hard if impossible to translate scientific findings into clinical practice. For instance, when the Grenoble team developed deep brain stimulation back in the 80ies and 90ies, they needed a strong industry partner to bring their breakthrough therapy into clinical practice. In some of the upcoming episodes including the present one, I will interview executives from the device industry. Who better to start this journey with than Todd Langevin, who has been a key figure in the field of DBS and neuromodulation on the industry side. Following the success of Benabid's team in Grenoble, inside Medtronic, Todd led the internal venturing team that pitched, developed and launched DBS, which is now an $800M business worldwide. So – in a sense – we may owe it to Todd's team similarly as much as to the scientific and clinical team of investigators in Grenoble that DBS has become a therapy that is being applied, world-wide. During his 20 years at Medtronic, Todd grew the DBS business to a $350 million unit revenue. After a brief hiatus in the cardiac world, he moved back into the field of DBS to lead the startup Functional Neuromodulation as CEO, which aims at establishing DBS to the fornix as a treatment for Alzheimer's Disease. Indeed, under Todd's leadership, the company achieved a CE mark for the treatment in Europe. Finally, in 2021, Todd moved to Biotronik, where he currently is the President of the Neuromodulation Business.

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Michael A. Rosenberg, MD, FHRS, of University of Colorado Anschutz, and Jagmeet P. Singh, MD, PhD, FHRS, of Massachusetts General Hospital to discuss early detection of atrial fibrillation (AF) may help prevent adverse cardiovascular events such as stroke. Deep learning applied to electrocardiograms (ECGs) has been successfully used for early identification of several cardiovascular diseases. Deep learning of outpatient sinus rhythm ECGs predicted AF within 31 days in populations with diverse demographics and comorbidities. Similar models could be used in future AF screening efforts to reduce adverse complications associated with this disease.   https://www.hrsonline.org/education/TheLead https://jamanetwork.com/journals/jamacardiology/article-abstract/2810388   Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic   Contributor Disclosure(s): M. Rosenberg: No relevant financial relationships with ineligible companies to disclose.  J. Singh: Honoraria/Speaking/Consulting Fee: Medtronic, EBR Systems, Boston Scientific, Biotronik, Abbot, MicroPort Scientific Corporation, Cardiologs, Sanofi, CVRx Inc., Impulse Dynamics, USA, Implicity, Orchestra Biomed, Rhythm Management Group Corp, Medscape, Biosense Webster Inc., Notal Vision, iRhythm Technologies, Philips

Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College, discusses the CAST trial with David J. Callans, MD, FHRS, CCDS of Hospital of the University of Pennsylvania, and Gerald V Naccarelli, MD, FHRS of Pennsylvania State University Milton S. Hershey Medical Center. Class IC antiarrhythmic drugs have been generally avoided in patients with any degree of coronary disease and any type of cardiomyopathy, whether or not they fit the inclusion criteria of the trial. For the past 3+ decades, the CAST trial results have been extrapolated to a broader population despite a lack of evidence. In this study, the authors retrospectively look at the safety of these agents compared with Class III drugs in patients with atrial fibrillation and varying degrees of CAD.  https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacep.2022.12.021 Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stocks (Privately Held): Atlas 5D Contributor Disclosure(s): D. Callans: Honoraria/Speaking/Consulting: Heart Rhythm Society, Thermedical, AtriCure, Inc., Abbott Medical, Biosense Webster, Volta Medical, Mediasphere Medical, Coherex, American College of Cardiology, Best Doctors, Bayliss Medical, Biotronik, Boston Scientific, Impulse Dynamics USA: Fellowship Support: Biosense Webster, Biotronik, Boston Scientific, Medtronic, Abbott; Other Financial Relationships: Wolters Kluver G. Naccarelli: Honoraria/Speaking/Consulting: Acesion, Sanofi, GlaxoSmithKline, Milestone, InCarda Therapeutics

Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College discusses A Novel ECG-Based Deep Learning Algorithm to Predict Cardiomyopathy in Patients With Premature Ventricular Complexes with Daniel Frenkel, MD, FHRS, of Westchester Medical Center, and Jagmeet P. Singh, MD, PhD, FHRS, of Massachusetts General Hospital. This study utilized a machine learning algoritihm to predict the devlopment of cardiomyopathy in patients with PVCs based on the baseline ECG.   https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacep.2023.05.025   Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stocks (Privately Held): Atlas 5D   Contributor Disclosure(s): D. Frenkel: Ownership/Partnership/Principal: Summit Health J. Singh: Honoraria/Speaking/Consulting Fee: Medtronic, EBR Systems, Boston Scientific, Biotronik, Abbot, MicroPort Scientific Corporation, Cardiologs, Sanofi, CVRx Inc., Impulse Dynamics, USA, Implicity, Orchestra Biomed, Rhythm Management Group Corp, Medscape, Biosense Webster Inc., Notal Vision, iRhythm Technologies, Philips

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, October 6, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Nuro this week announced it achieved communication with a locked-in patient with its neurotechnology. Fast Five hosts Sean Whooley and Danielle Kirsh talk about the technology and what allows the patient to communicate. Biotronik published positive data for its spinal cord stimulation technology. Whooley explains the technology and what some of the most important data points were from the study. Dexcom has launched its next-generation G7 continuous glucose monitor in Canada. Hear when the device is slated to hit the market, who it's designed for and what executives think about the launch. Medtronic appointed a new president of neuromodulation this week. Find out who is taking over this role and some of their career history.  Precision Neuroscience has received an FDA breakthrough nod for its brain-computer interface technology, and purchased a new factory in Texas. The Fast Five hosts discuss the technology and what the new foundry location will house.

Implantable continuous glucose maker Glucotrack announced it has a new VP of marketing. Fast Five hosts Sean Whooley and Danielle Kirsh talk about the new VP and their career history that supports the appointment. Haemonetics is expanding its global presence by launching its vascular closure device in Europe. Find out which device is going global, how it works and what's next for Haemonetics. The FDA granted 510(k) clearance to ICU Medical's infusion pump and software. Whooley explains what the they do and some of the features that make patient monitoring seamless. Pediatric devices is an underserved market, and PolyVascular and CobiCure are looking to fix that with a new partnership for non-surgical pediatric heart valves. Hear more about the partnership and what kinds of resources and funding the companies have. Biotronik has implanted its next-gen pacemaker in its first patients. Whooley details what the Anmia Edge is designed for, what benefits it offers and what doctors think about the device. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Magnetic Resonance Imaging, pacemakers and ICDs Tough problems in the treatment of hypertension Snapshots Host: Rick Grobbee Guests: Stephan Achenbach, Chiara Bucciarelli-Ducci, Christophe Leclerq, Bryan Williams. Want to watch that episode? Go to: https://esc365.escardio.org/event/1123   Disclaimer This programme is supported by Siemens Healthineers in the form of an educational grant. The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Chiara Bucciarelli-Ducci has declared to have potential conflicts of interest to report: CEO (part time) of the Society for Cardiovascular Magnetic Resonance. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.  Christophe Leclerq has declared to have potential conflicts of interest to report: lectures and consultancies for Abbott, Biotronik, and Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.  Bryan Williams has declared to have potential conflicts of interest to report: chair of steering committees for trails for Novartis and AstraZeneca.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Edge-to-edge mitral valve repair The future treatment of chronic heart failure Mythbusters: Is chocolate healthy for the heart? Host: Susanna Price Guests: Carlos Aguiar, Milton Packer and Stephan Windecker Want to watch that episode? Go to: https://esc365.escardio.org/event/1122   Disclaimer This programme is supported by Siemens Healthineers in the form of an educational grant. The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Milton Packer and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme. Stephan Windecker has declared to have potential conflicts of interest to report: payments from Amgen and Medtronic, research funding from Abbott, Amgen, AstraZeneca, Bayer AG, Biotronik, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Guerbet AG, Johnson & Johnson, Medtronic, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi Adventis, V-Wave, Abiomed, Boehringer-Ingelheim, Bristol Myers Squibb, B.Braun, Cordis Medical, Miracor medical, Pharming Tech, CSL Behring, Farapulse Inc., Fumedica, Idorsia, Inari Medical, MedAlliance.

A Discussion of Left Bundle Branch Area Pacing Versus Biventricular Pacing as the Initial Implant Strategy for Cardiac Resynchronization Therapy. Danesh Kella, MBBS, FHRS of the Mayo Clinic, Florida hosts a discussion with co-host Jason T. Jacobson, MD, FHRS of Westchester Medical Center and guests Roderick Tung, MD, FHRS of the University of Arizona – Phoenix, and Rajeev Kumar Pathak, MBBS, PhD, FHRS of Australian National University and Canberra Hospital. This episode was recorded live at Heart Rhythm 2023 in New Orleans, Louisiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stock Ownership: Atlas 5D D. Kella: No relevant financial relationships with ineligible companies to disclose. Contributor Disclosure(s): R. Pathak: No relevant financial relationships with ineligible companies to disclose. R. Tung: Honoraria/Speaking/Consulting Fee: Abbott, AtriCure, Biotronik, Boston Scientific, Medtronic

In this episode of DeviceTalks Weekly we'll talk with Mike Favet, CEO of NeuroPace, about how the company's RNS technology is helping to transform the lives of patients with drug-resistant epilepsy. NeuroPace, one of the pioneers in neurostimulation, has the only FDA-approved neurostim treatment for epilepsy. Favet took over as CEO four years ago from the founding CEO so we discuss his background, the changes he made at the company, and how NeuroPace is building a market for a medical device to treat a disease that typically can be managed only by pharmaceuticals. Mike Favet will be a panelist on a keynote panel about building a neuromodulation market at DeviceTalks West on Oct. 18-19 at the Santa Clara Convention Center. Co-hosts Tom Salemi and Chris Newmarker introduce a new formula for the Newmarker's Newsmaker. Companies mentioned including Philips, Biotronik, Medtronic, Johnson & Johnson, GE Healthcare, Depuy Synthes, BD, and many others. Thanks for listening to the DeviceTalks Podcast Network. Subscribe to this network on any major podcast app.

The availability of Insulet's Omnipod 5 automated insulin delivery system in the UK is a significant development in diabetes management. Fast Five hosts Sean Whooley and Danielle Kirsh explain the system's impact on people with diabetes in the regions where it is already available and where the company plans to launch next. Teleflex's partnership with Insighters Medical to distribute Insighters' video laryngoscope is an exciting development in airway management. Whooley provides the details of the partnership and what Insighters technology does for patients and providers.  A new partnership between GE Healthcare and DePuy Synthes allows GE HealthCare's imaging technologies and DePuy Synthes' orthopedic solutions, aiming to optimize surgical planning and improve the accuracy of spinal procedures. The Fast Five hosts discuss the technology being shared and how this partnership complements GE Healthcare's ongoing partnerships. The partnership between Philips and Biotronik signifies a joint effort to enhance care delivery in out-of-hospital cardiology labs. This collaboration aims to combine Philips' expertise in remote monitoring and digital health solutions with Biotronik's innovative cardiovascular technologies. Hear how the combination of technologies will affect patients. Surgalign's decision to file Chapter 11 bankruptcy to sell its global hardware and biologics business is a strategic move aimed at restructuring and focusing on core operations. The Fast Five hosts talk about what the asset purchase agreement states and if the company plans to continue operating as usual.  Check out the show notes at MassDevice.com/podcast.

Each episode of Reorg's weekly EMEA Core Credit podcast series features detailed discussions on issues and companies across the credit lifecycle. This week's podcast includes discussions on: Trends in European high-yield bonds that were assigned a double B rating in 2022; Topical restructuring updates on companies including Biotronik, SLV and Flint; New reports of Asda acquiring EG Group's U.K. forecourt business; and Primary highlights for the week. We're looking for feedback to improve the podcast experience! Please share your thoughts here: www.research.net/r/Reorg_podcast_survey #leveragedfinance #highyieldbonds #restructuring #debtrestructuring #distresseddebt #performingcredit #leveragedloans #highyield

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Cardiac involvement in Fabry's Disease Anti-thrombotic therapy post PCI: DAPT in 2023  Mythbusters: Powernap for heart health Host: Rick Grobbee Guests: Perry Elliott, Nicolle Kraenkel, Roxana Mehran and Franz Weidinger Want to watch that episode? Go to: https://esc365.escardio.org/event/896 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes.  The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.  Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests  Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Franz Weidinger have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.  Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.  Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Sanofi. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll;  personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, WebMD; Equity

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Update on indications and methods for Patent Foramen Ovale (PFO) closure Incidence, outcome, acute and chronic treatment of Spontaneous Coronary Artery Dissection (SCAD) Mythbusters: The earlobe crease Host: Rick Grobbee Guests: Carlos Aguiar, Lorenz Raeber and Jacqueline Saw Want to watch that episode? Go to: https://esc365.escardio.org/event/802 Disclaimer: This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Jacqueline Saw declared to have no potential conflict of interest to report. Carlos Aguiar declared to have potential conflict of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno declared to have potential conflict of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Lorenz Raeber declared to have potential conflicts of interest to report: Consultation/speaker fees from Abbott, Amgen, AstraZeneca, Canon, Medtronic, Novo Nordisk, Occlutech, Sanofi. Research grants to the institution by Abbott, Biotronik, Heartflow, Sanofi, Regeneron. Emma Svennberg declared to have potential conflict of interest to report: Institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Você já fez ou já viu um eletrocardiograma? Hoje trouxemos o Leomar Zeferino, Biomédico especialista em estimulação cardíaca artificial e Assessor Técnico na Biotronik. Ele nos contou um pouco sobre a história dele e trouxe... O post #121 Estimulação Cardíaca Artificial – Entrevista com Leomar Zeferino apareceu primeiro em Biomedcast.

In this month's Digital Health Roundup, Medtech Insight's Reed Miller talks about Biotronik's and AliveCor's partnership, Marion Webb profiles three agetech companies, and Barnaby Pickering talks Swiss medtech awards and smart hospitals. Listen to the podcast via the player below: Medtech Insight articles addressing topics discussed in this episode: Minute Insight: AliveCor And Biotronik Pilot Combined Remote Cardiac Monitoring Solution Exec Chat: ‘Wow Factor' Is Important In Medtech Investment, But It's Not Everything Says Ceros CEO ‘The Story That No One Likes To Hear': Investors Looking For Surer Bets In Health Tech After Record 2021' MedRhythms On First-To-Market Track With Prescription Music Therapy For Chronic Stroke VR Technology Offers Real-World View Of What It's Like To Live With Age-Related Impairments De Oro Devices' NexStride To Help Freezing Gait Is Targeting Expansion To Other Diseases, Software Integration Minute Insight: Amazon Gives Up On Amazon Care, Shifts Focus To Acquisitions Medtech Innovators Take on Fall Prevention, Mobility Challenges For Older Adults De Oro Devices' NexStride To Help Freezing Gait Is Expansion To Other Diseases, Software Integration

Schlägt das Herz nicht mehr im Takt, kommt oft ein Herzschrittmacher zum Einsatz. Darauf folgen regelmäßige Kontrolltermine, bei denen die Messdaten aufwendig manuell ausgewertet werden. Doch was wäre, wenn der Herzschrittmacher selbstständig und regelmäßig diese Daten an den behandelnden Arzt schickt und dieser bei Auffälligkeiten direkt eingreifen kann, noch bevor sich der Zustand des Patienten verschlechtert? Mit dem vernetzten Herzschrittmacher von Biotronik können Auffälligkeiten schnell erkannt und so die Sterblichkeitsrate um 60 % gesenkt werden. Ihr wollt mehr erfahren? Dann hört rein!

Compliance into the Weeds is the only weekly podcast which takes a deep dive into a compliance related topic, literally going into the weeds to more fully explore a subject. In this episode, we take a deep dive into the recent settlement by Biotronik with the DOJ over allegations of the violation of the Anti-Kickback Statue  Highlights include: ·      Background facts. ·      Training programs as cover for bribes. ·      What is lavish entertainment? ·      What were the internal control failures? ·      Controls for high-risk payments. ·      Lessons learned for the ABC compliance professional. Resources Tom in the FCPA Compliance and Ethics Blog Part 1-Background Part 2-the Bribery Schemes and Lessons Learned Matt in Radical Compliance Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to the podcast! In a recent episode, Joel, Hope, and I discussed the 3 Game-Changing Strategies that JMOs can employ to maximize their transition. The podcast is based on a recent transition guide with the same title. The first strategy we recommend is to find opportunities where a JMO can build a track record of success, typically within three to five years. In this episode, you will meet Mike Scheer. Mike is a former Army Special Operations officer who transitioned in 2014 after being an ODA Commander. Mike is someone who approached his career search with these strategies. Mike launched his career at BIOTRONIK, a world leader in cardiac rhythm management (CRM) technology. Like most jobs that he went into in the military, Mike was thrown into a technical, challenging, and rewarding role. He was able to use his drive, emotional intelligence, and intellect to make an immediate impact for his customers. He launched his career in an industry-leading company and in a role that allowed him to build a strong track record of success. After Mike's busiest customer relocated to a different part of Washington, Mike had an important decision to make - either move near his customer or use his track record to transition to another opportunity. He chose the latter and went to work for Nevro. Nevro is another industry-leading company! They provide neuromodulation solutions to help patients deal with chronic and debilitating pain. Mike began at Nevro without much momentum in his market, quickly built his territory and is continuing to expand it. His experience is another example of a non-traditional business candidate (JMO) getting into the right company and right position in order to build a track record that will continue to carry him to great successes in his career. Mike also mentioned the book, Never Enough by Mike Hayes. Mr. Hayes is the former Commander of Seal Team 2 and Mike's former boss. I just ordered my copy and look forward to reading it. The proceeds of the book go to help pay off the mortgages for Gold Star Families. I hope you enjoy listening to my conversation with Mike as much as I enjoyed the conversation. If you're interested in learning more about why companies hire from Cameron-Brooks, contact us! You can also check out our Transition Guide on "3 Game-Changing Strategies for JMOs Making the Jump to Business" for additional transition tips. To stay connected, we'd recommend subscribing to our YouTube Channel and following us on LinkedIn.

“Design's superpower is to evolve abstract into concrete”— DOGAN SEKERCIOGLUIn this episode, we chat with Dogan Sekercioglu, who is a former Industrial Design Lead from IDEO and currently works on future robotic and medical designs at Intuitive in California. With Dogan we chat about the interplay between abstract and concrete and how it's actually a superpower of the designer.Throughout the episode, he shares his learnings from projects where he had worked, which made a positive impact on the world.We also talk about his experiences working on sustainability design projects and how changing the question from solving to reducing can actually open up new opportunities for innovation that might be just an iteration but also a step forward because moving is better than not moving. In the episode, we jump into:The role of advanced design when it comes to designing complex systems.How can constraints and requirements and fighting them, and questioning them could lead to product innovation?What are the key challenges in designing in the medical space?Why is “creative” not a department but a culture?and many more!Thanks a lot for your time and for your learning Dogan!*****The GuestDogan Sekercioglu is currently a Senior Industrial Designer at Intuitive, focusing on developing human-centred solutions to improve patient outcomes in minimally invasive robotic surgery.His previous consulting experience at IDEO as an industrial design lead spans medical tools & robotics, autonomous mobility UX, lifestyle, and consumer electronics.He has helped shape future product experiences for Johnson & Johnson (Auris), Ford, ConAgra, Biotronik, Medtronic, Atlas Copco, Timberland, Jordan, and Cisco.Dogan is passionate about infusing human insights with craft excellence to deliver delightful products.He has deep experience designing for dynamic hardware systems such as autonomous vehicles and robotics, seeking design opportunities in often ignored physical transitions.

Wie baut man das Employer Branding eines Hidden Champion auf? Jörg Seufert von Biotronik kennt sich da aus und teilt sein Wissen mit uns!

This episode is sponsored by Davwill Consulting. Emotional agility? Yep, it's needed more now than ever. Let's chat! Click Here As an advisor, consultant, and executive coach, Dan Norenberg enables business leaders and leadership teams to improve their performance, strategy, and organizational results. His professional career started in California, where he led sales and marketing teams for two technology firms, gaining recognition for his business results and innovative approaches to developing people and teams. Later he started his own consultancy practice and was nationally recognized for achievements in people development and performance. He spent nearly a decade working in California before moving to Europe. After coming to Europe, he spent three years with the Siemens AG as a lead facilitator for business communication and intercultural management programs. Later he founded N Vision Learning Solutions GmbH, a leadership consultancy based in Munich. At N Vision Learning, he was the Managing Director and Senior Learning Partner, helping senior clients improve their leadership team performance to drive strategic success and create cultures of ownership. His educational background is in psychology and criminology. He is a certified Marshall Goldsmith Stakeholder Centered Coach®, a Narrative Coach Certified Practitioner™ and a member of the Society of the Advancement of Consulting. He has completed post graduate work in strategic selling and negotiating, cross-cultural dynamics, conflict, executive coaching, strategy development and team building. He is a certified facilitator for IDI®, ICI®, MBTI® and the Structogram®. He has designed and delivered leadership and business growth initiatives in 17 countries in Asia, Europe, and North America. Some of his past and current clients include the Allianz Group, Biotronik, BMW, Ciba Vision, COWI, Dentsply Sirona, the European Patent Office, Gilead Sciences, Hartmann Group, Infineon, IWIS, Klosterfrau, Knorr-Bremse, LEGO, Merck, Rohde & Schwarz, The Walt Disney Company, UBS and ZF. Connect with Dan at: https://www.linkedin.com/in/dannorenberg/ https://www.dannorenberg.com/

The MDR classification was hidding some surprises and I have asked Frank Matzek from Biotronik to tell us more about the products and rules we need to take care of. So Enjoy! The post Let’s unleash “MDR Classification surprises” [MDR 2017/745] appeared first on Medical Device made Easy Podcast.

Executive Advisor Dan Norenberg joins Maria Villablanca to explore what makes high-performing leaders and teams, drawing on his experience of coaching over 100 executive teams. Dan unpicks the importance of creating a culture of ownership and consistent reflection on how to improve the little things that can have a tremendous impact on performance when combined. Putting Maria in the hot seat, Dan uses his coaching prowess to help explain some of the key themes of his book Executive Ownershift: Creating Highly Effective Leadership Teams".   About the Speakers Dan Norenberg improves leadership performance and organization results through Executive Ownershift, his transformational growth process for executive teams. As a trusted advisor, consultant and professional speaker, Dan's mission is to enable executive teams and their organizations to play at their best. He's advised over and coached over 100 executive and senior leadership teams and has led leadership growth initiatives in over 17 countries, and his clients include the Allianz Group, Biotronik, Ciba Vision, Dentsply Sirona, the European Patent Office, IWIS, Klosterfrau, Knorr-Bremse, Lego, Rohde & Schwarz, The Walt Disney Company, UBS and ZF TRW.

Für die Unternehmen in der Medizinaltechnik ging es jahrelang nur in eine Richtung: aufwärts. Die Branche verzeichnete lange zweistellige Wachstumsraten. Zuletzt sind aber auch dunkle Wolken aufgezogen. Wir analysieren den Zustand der Schweizer Medtech mit zwei Experten im «Tagesgespräch». Implantate, Messgeräte, Hörhilfen: Die Medizinaltechnik boomt, und obwohl die Branche global aufgestellt ist, setzen viele Unternehmen – vom KMU bis zum Grosskonzern – gezielt auf den Produktionsstandort Schweiz. Das bringt eine hohe Wertschöpfung und gute Positionen in den internationalen Innovationsrankings. Mit einer Exportquote von 65 Prozent und den meisten Patenten pro Einwohner in ganz Europa, ist die Medizinaltechnik-Industrie für die Schweiz von grosser volkswirtschaftlicher Bedeutung. Doch die Corona-Pandemie kühlte den Boom zunächst etwas ab, und neue Handelshemmnisse mit der Europäischen Union wegen des verhinderten Rahmenabkommens sorgen für Alarmstimmung in der Branche. Am heutigen Swiss Medtech Day in Bern trifft sich, was in der Medizinaltechnik Rang und Namen hat. Gelegenheit für Marc Lehmann, genauer hinzusehen: Mit dem Geschäftsführer des Branchenverbands Swiss Medtech, Peter Biedermann, und mit Daniel Bühler – erst ist Direktor von Biotronik, eines internationalen Unternehmens, das auf Herzschrittmacher und Defibrillatoren spezialisiert ist.

Joining us for a second time on the Healthcare Corner is Dr. Gil Ungab, sharing his knowledge of the hot topic of healthcare inequality. Why does it exist? If you are in a minority group in the U.S., how are you affected? When it comes to drug trials, the industry needs to make an effort to include all ethnicities. How does COVID-19 come into play with inequalities for all communities? Come join us today to learn more about how we can work together to represent all individuals. Dr. Gil UngabDr. Gilanthony Ungab, M.D., is a cardiology specialist in National City, California, and has over 27 years of experience in the medical field.  He graduated from the University of California, San Diego, School of Medicine, in 1994.  He is a private practice cardiac electrophysiologist and former Medical Director of Cardiac Electrophysiology at Sharp Chula Vista Medical Center in San Diego, California. He served as a member on research and development committees at Boston Scientific, St. Jude, and Biotronik.

O lidské duši a mezilidských vztazích mluvil v Dobrém dopoledni Českého rozhlasu Vysočina biotronik Tomáš Pfeiffer.

O lidské duši a mezilidských vztazích mluvil v Dobrém dopoledni Českého rozhlasu Vysočina biotronik Tomáš Pfeiffer.

Join us for our conversation on Atrial Fibrillation (AFib or AF) featuring our special guest Dr. Gil Ungab. AFib is a serious diagnosis. While this condition isn't fatal in itself, it can lead to potentially life-threatening complications. Two of the most common complications of AFib are stroke and heart failure, both of which can be fatal if not managed quickly and effectively. Dr. Gil UngabDr. Gilanthony Ungab, M.D., is a cardiology specialist in National City, California, and has over 27 years of experience in the medical field.  He graduated from the University of California, San Diego, School of Medicine, in 1994.  He is a private practice Cardiac Electrophysiologist and former Medical Director of Cardiac Electrophysiology at Sharp Chula Vista Medical Center in San Diego, California. He served as a member on research and development committees at Boston Scientific, St. Jude, and Biotronik.

CM Medical's Henry Bell hosts this episode of CM Conversations, which is all about cardiac digital health and data. To take on this exciting topic, Henry's joined by Ken Nelson - Head of Digital Health, Diagnostics, & Monitoring at Biotronik. Ken has spent over 20 years in the cardiovascular device market, working at the likes of Boston Scientific, iRhythm Technologies, BioTelementry Healthcare, Bardy Diagnostics and now Biotronik. Together, Henry and Ken discuss how cardiology is becoming more data-dependent and what he thinks about the future of the space. We hope you enjoy listening and if you have any feedback about the episode, please feel free to email Henry at Henry.Bell@medical-cm.com. For more med-tech content like this, please go to www.searchingmedical.com.

Con Marga de la Fuente, y con el Doctor Javier Cabo, cirujano cardiovascular y especialista internacional, conocimos la actual situación del Covid-19. ¿Cuándo estarán disponibles las vacunas para su uso? ¿Podemos reinfectarnos? Mutación del virus y los actuales tratamientos. Con Yago Alonso, director en España de la multinacional Biotronik, conocimos la importancia de la innovación tecnológica en el campo de la cardiología, los dispositivos más punteros con tecnología telemática. La telemedicina como pieza clave para controlar nuestra salud y los productos estrella de esta compañía líder.

For years, medtech companies have known connectivity was good for them, but the promise of data streaming through devices didn't match the reality. COVID-19 changed that, creating an opportunity for device companies with connectivity plans in place. In this episode, we speak with Dr. David Hayes, CMO of Biotronik, about that companies success in connecting cardiology patients. Meanwhile, Bill Betten of S3 Connected Health explains what device companies must do to prepare for medtech's next age. We also review the week's top news involving Medtronic, Johnson & Johnson, Abbott, Edwards, and Smith+Nephew

Con Marga de la Fuente, hablamos sobre cómo las empresas de eventos, comunicación, relaciones públicas, emprendimiento animal, medicina, ciencia, tecnología, marketing han hecho frente a la pandemia, qué ha cambiado en estos sectores y hacia donde se dirigen. Nos acompañó Carlos González, Director de Comunicación y RR.PP. Cristina Álvarez, Directora y Presentadora de Reino Animal. Ángel Madrid, Director Clínico y Medical Affair de Biotronik y Cristian Vidal, CEO de Belvi y Tecnólogo.

En este programa Marga de la Fuente, nos acerca a los últimos avances en medicina regenerativa, biotecnología, criopreservación y farmacología. El Doctor Javier Cabo, cirujano cardiovascular , Presidente de QALY advanced y Fundación VidaPlus, nos habló sobre su proyecto QALY, un innovador proyecto focalizado en vivir más y con mejor calidad de vida, y prevenir posibles enfermedades, . Con Oscar Mesa, CEO de Qualitecfarma, conocimos dos ensayos clínicos que están realizando con LAMINAR Pharma, dirigido a el glioblastoma y NEUROFIX, dirigido al dolor neuropático en lesionados medulares. Contamos con la colaboración especial de Ángel Madrid, Director Clínico y Medical Affair de Biotronik. Nos acompaño en el programa Luis Carlos Hernández, director de la división vascular de Biotronik.

The world is moving at an ever increasing pace yet leaders are becoming more and more bogged down by everything which they are expected to achieve. Sometimes the best strategic is not actually learn how to speed up but rather how and when to slow down. Liz Bywater has been called a one-of-a-kind leadership expert. Working at the intersection of business and psychology, Liz integrates deep expertise in human behavior and organizational dynamics with a pragmatic mindset and engaging personal style to help her executive clients thrive in an increasingly complex world. Liz works with top executives and management teams across an array of companies, including Johnson & Johnson, Bristol-Myers Squibb, AmerisourceBergen, Nike, Boeing, Northrop Grumman, Biotronik, EMD Serono, Thomson Reuters and more. She provides her clients with expert guidance and pragmatic tools to accelerate success, based on more than 25 years of experience Slow Down to Speed Up Topics During this interview, Liz and I discuss the following topics: What it truly means to slow down in order to speed upWhy racing to results is ineffectiveWhen and how leaders should take a breakHow leaders can in place barriers from workWhy reflection is so importantHow leaders can ensure that they are on the right trackHow to ensure you thrive at work Guest Resources If you are interested in Liz and her resources then be sure to check out the following links: Slow Down to Speed Up BookSample ChapterLiz’s websiteLiz on LinkedInLiz on TwitterLiz on Facebook Moving Forward Leadership Resources Keep on top of Moving Forward Leadership with all the resources which I have established for you, free of charge: POWER Goals Program - If you are ready to stop complaining and start achieving those goals which you have been trying to achieve for some time now. Then stop chasing your dreams and start achieving them through my very own POWER Goals program. Learn about picking the right goals, figuring out how to achieve them, getting on track with achieving them and most importantly how to get back on track when you fail... because you will. Learn more here! Moving Forward Leadership Resources - Check out the Moving Forward Leadership Resources section where I list every single resource mentioned on the show. As well, there are books which I have read written or read personally and finally various types of services which I use and recommend. The 9 Foundations of Leadership – I’ve written this ebook for you all to get a base of your leadership skills. With this book, you will be able to begin to form your leadership style. For a small fee, you can get your journey started and get ahead of your peers! Just follow the link in the title, and your copy awaits you! Facebook Page – Check out updates from Moving Forward Leadership, as well when links and videos. Facebook Group – Come and let’s discuss leadership. I will swing by and answer any questions you have as well as provide advice and guidance for your situations. Twitter – Definitely subscribe here to find out when new episodes go live, or if I have a random idea to share with the world. Monthly Newsletter – Sign up for my newsletter and see what is happening in the background with me, read the most interesting articles in leadership, as well as get inside information from time-to-time on what I have upcoming! Email – Don’t hesitate to reach out to me with ideas, suggestions, comments or questions. I truly love hearing from you all! Where to Subscribe to Moving Forward Leadership Love the Moving Forward Leadership Podcast? Then subscribe to your favourite device and app! As well, please leave me a review! These reviews mean more to me than you could ever imagine.

En este programa con Marga de la Fuente, conocimos algunos de los avances en investigación y biotecnología, de la mano de Óscar Mesa del Castillo, fundador y CEO de Qualitecfarma empresa de investigación clínica e industria farmacéutica. Noelia Beltrán, la inventora del primer producto protector textil antimicrobiano. Ángel Madrid, director de investigación médica de Biotronik, empresa de tratamiento de enfermedades cardiovasculares. Miguel Ángel Llamas, CEO Empireo, donde habla de la importancia del diagnóstico y prevención de las ITS. Nos acompaña Samuel Benzadon, experto en coach estratégico.

This week, your hosts Steve Lowry and Yvonne Godfrey interview Randi McGinn of McGinn, Montoya, Love & Curry. P.A. (MMLC) - www.mcginnlaw.com   Remember to rate and review GTP in iTunes: Click Here To Rate and Review   Case Details:   Sowards v. Biotronik, wrongful implant of a pacemaker in exchange for kickbacks.   Read More Here   Click Here to Read/Download the Complete Trial Documents (Plaintiff's Opening, Plaintiff's Closing, Special Verdict Form Compensatory/Punitive Damages)   Guest Bio: Interesting Stuff Randi McGinn is the author of “Changing Laws, Saving Lives: How to Take on Corporate Giants and Win,” available through Trial Guides at http://www.trialguides.com/book/changing-laws-saving-lives/ She is one of the country's leading trial lawyers, having tried over 130 cases, including those of women survivors of sexual assault, harassment, and retaliation. The first woman president of the Inner Circle (100 best trial lawyers in the US), she is known for her creativity in the courtroom and use of demonstrative evidence to visualize opening, direct, cross-examination and closing argument. She has destroyed adverse witnesses by leaving a pretentious Beverly Hills doctor standing in front of the jury covered with post-its and clutching a grapefruit to his chest, by grilling a government snitch until he threw up and by exposing the fact that a world-renowned polygraph expert had been polygraphing his own sperm cells in the dead of night. In a particularly hard-won police shooting case, the local SWAT cops once put her face on their Christmas pinata and took turns whacking it with a big stick. She recently was appointed as a special prosecutor and tried the first murder prosecution in over 50 years of an Albuquerque police officer for an on the job shooting. Started her career by giving birth to daughter Heather, now age 38, the day before the 3-day bar examination. Boring Stuff A senior partner with her three women partners in a law firm in Albuquerque, New Mexico; double listed in criminal and civil litigation in Best Lawyers in America; International Academy of Trial Lawyers fellow; past AAJ Governor; past president of the New Mexico Trial Lawyers' Association; NACDL board member, NITA-NCDC-UNM adjunct instructor. Randi's Full Bio     Show Sponsors   Legal Technology Services - LTSatlanta.com   Digital Law Marketing - DigitalLawMarketing.com   Harris, Lowry, and Manton - hlmlawfirm.com     Free Resources: Stages Of A Jury Trial - Part 1 Stages Of A Jury Trial - Part 2  

In today's hyper-competitive markets, employees can be a business' biggest naturally occurring and untapped asset. Our discussion today centres on why biomedical technology company, Biotronik is deliberately allocating resources (financial & time) to partner its employees as a means to extending the brand's social reach. You can find out more about theIntern-Ship on www.theintern-ship.co.za or catch them on Twitter and LinkedIn. A big thank you to our friends at Nfluential for making sure conversations happen and the coffee keeps flowing! Contact them - they are Influencer Marketing Strategists and will propel your business to startling success. For more info on Nfluential, visit www.nfluential.co.za. Nfluential Influencer Marketing Strategists

Echocast Radio — In today's hyper-competitive markets, employees can be a business’ biggest naturally occurring and untapped asset. Our discussion today centres on why biomedical technology company, Biotronik is deliberately allocating resources (financial & time) to partner its employees as a means to extending the brand’s social reach. You can find out more about theIntern-Ship on www.theintern-ship.co.za or catch them on Twitter and LinkedIn. A big thank you to our friends at Nfluential for making sure conversations happen and the coffee keeps flowing! Contact them - they are Influencer Marketing Strategists and will propel your business to startling success. For more info on Nfluential, visit www.nfluential.co.za.

I'm so excited to finally share the chat we recorded on our whirlwind trip to Seoul for the global Nike Joyride launch. It was such an incredible experience especially at the peak of my non-runner to running-lover conversion and so cool to head back to the motherland after 17 years (a long story that I'll tell another day). After he hosted the global launch event, I was so lucky to sit down with Nike Senior Product Line Manager, Will Moroski, to chat in more detail about this incredible shoe as well as sharing his own amazing way to yay in the process. Another wonderful example of ending up exactly where you never expected but where you were absolutely meant to be. While nurturing a love for sport from very young, Will's nerdy side also flourished through his journey. While competing seriously in track and field, he started college at UC Davis undeclared but then found himself in biomedical engineering. Loving it so much, while others took a gap year, Will headed to Oxford to do his Masters in Biomedical Engineering completing a casual thesis on Malaria in Pregnancy: Assessment of Effect Using Image Texture Analysis. This then took him to Thailand for field work and research followed by a clinical studies engineer position at pacemaker company Biotronik. It was Biotronik that moved him to Portland, the home of Nike HQ, where he found himself teaching spin classes to Nike staff who encouraged him to make the jump. Five years later, he's working on world class innovation and changing runner's lives with new technology. I'll let him tell you the rest but hope you enjoy!!!! + Full show notes here + Announcements on Insta at @spoonful_of_sarah + Subscribe to not miss out on the next instalment of YAY!

I’m so excited to finally share the chat we recorded on our whirlwind trip to Seoul for the global Nike Joyride launch. It was such an incredible experience especially at the peak of my non-runner to running-lover conversion and so cool to head back to the motherland after 17 years (a long story that I’ll tell another day). After he hosted the global launch event, I was so lucky to sit down with Nike Senior Product Line Manager, Will Moroski, to chat in more detail about this incredible shoe as well as sharing his own amazing way to yay in the process. Another wonderful example of ending up exactly where you never expected but where you were absolutely meant to be.While nurturing a love for sport from very young, Will’s nerdy side also flourished through his journey. While competing seriously in track and field, he started college at UC Davis undeclared but then found himself in biomedical engineering. Loving it so much, while others took a gap year, Will headed to Oxford to do his Masters in Biomedical Engineering completing a casual thesis on Malaria in Pregnancy: Assessment of Effect Using Image Texture Analysis. This then took him to Thailand for field work and research followed by a clinical studies engineer position at pacemaker company Biotronik. It was Biotronik that moved him to Portland, the home of Nike HQ, where he found himself teaching spin classes to Nike staff who encouraged him to make the jump. Five years later, he’s working on world class innovation and changing runner’s lives with new technology. I’ll let him tell you the rest but hope you enjoy!!!!+ Full show notes here+ Announcements on Insta at @spoonful_of_sarah+ Subscribe to not miss out on the next instalment of YAY!

In this edition of Device Week, Medtech Insight's Reed Miller chats with Marion Webb about her upcoming Market Intelligence story covering the global arthroscopy and sports medicine products market, based on Informa's new Meddevicetracker report, with a focus on the fast-growing hip arthroscopy market. Reed Miller discusses Biotronik's new BIO-LIBRA study designed to measure sex-specific outcomes in patients with non-ischemic cardiomyopathy treated with implantable cardioverter defibrillators (ICD) and cardiac resynchronization defibrillators (CRT-D). Listen to the podcast via the player below: For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR Medtech Insight articles addressing topics discussed in this episode: Biotronik Starts First ICD Study Designed To Measure Sex-Specific Outcomes https://medtech.pharmaintelligence.informa.com/MT125074/Biotronik-Starts-First-ICD-Study-Designed-To-Measure-SexSpecific-Outcomes

Viviane Gonçalves, Diretora de Acesso e Relações Governamentais da América Latina da Biotronik é apaixonada pelo seu trabalho. Ela dedica seu tempo entre a América Latina e seus filhos de uma maneira extraordinária. Neste episódio do Via Oral, Viviane conta quais as habilidades essenciais na liderança feminina e explica o papel de Acesso e Governo na Indústria Farmacêutica.#viaoral

Video version https://youtu.be/0IvTueu2wygHere I am, back with my third blog post. I must mention it was heartening (pun intended) to receive a plethora of feedback on my last post. The post was about heart monitoring devices and explored the role of implantable loop recorders (ILRs) and ECG machines in arrhythmia diagnosis. Feedback means people are listening, watching and reading. That’s a good feeling. Speaking of feedback, my post today dwells on remote home monitoring devices and if their feedback capabilities can and are being optimally utilized in the world of EP.Over the years, the capabilities of implanted heart devices have grown exponentially, both in their therapeutic and diagnostic functions. However, this has translated into an increased burden on device clinics, as there is a large quantity of data being captured, which needs to be analyzed. This means specialists need to allocate more time to clinic patients. The increased longevity of patients, while a desired outcome, also means, that the device clinic must allocate more resources per patient over the years.Thankfully, with the advent of remote monitoring for implanted devices, the workload of routine analysis at physical clinics has begun to plateau. Such devices provide periodic telemetric transmission of patient’s heart readings via the internet to a secure cloud server. These readings can then be assessed by medical teams located at ‘virtual clinics’. They allow for early diagnosis of conditions and scheduling of physical visits, only when necessary. Over a period, this helps dodge acute complications in several cases. However, I think, the medical community is not completely prepared for a totally remote management of cases via such devices. To support my thought, I will present the case of a very close patient of mine.CASE STUDYA 72-year-old male with ischemic cardiomyopathy and severely reduced global systolic function, the ejection fraction or the capability of the heart, to pump out blood to the rest of the body, was reduced to 19%. To reduce the load on his heart and to synchronize the pumping of blood through his system, the patient was fitted with a CRT-D, a resynchronization therapy where the device functions as a cardiac pacemaker and doubles up as a defibrillator. In this case. His CRT-D also includes home monitoring; the overlying topic for this blog post. Additionally, the patient is on a daily dose of amiodarone (brand name: Procar), which helps lower heart rate & the number of ‘tachycardic’ events. Do note, the patient is 100% dependent on the pacemaker in order to have an underlying rhythm and pump blood.The patient presented on our “virtual clinic” with three days of reduced CRT pacing, manifesting physically as weak and unable to carry out tasks previously capable of, like walking up the stairs. On the analysis of the home monitoring data, we noted, only a reduced CRT pacing, which didn’t give away much. Here’s a look at the graph extracted from the Biotronik home monitoring system.Biotronik Graph AnalysisThe two-axis represents the percentage being paced and the time. Grey circles denote atrial pacing; blue is for right ventricle pacing and the fuschia triangles denote left ventricle pacing. The reduced CRT pacing appears to be a dangerous situation because this means the patient isn’t being paced 100% of the time, especially as he is a patient who is known to be pacing dependant. However, I cross-checked with his arrhythmic events diary to find a probable cause but there wasn’t any occurrence during these pacing drops. To investigate further, we called him in to for a device analysis and ECG.Biotronik ECG ReportAs we read the ventricle marker channels, we noticed sense events in left as well as right ventricle. In the third line, we saw a wide complex signal, not a standard normal signal. Now if you study the atrial signals below and compare it to ventricle signals, we know that there are more ventricle signals compared to the atrial signals. Getting to our basics, we know that when V is greater than A, it’s a ventricular tachycardia (VT). Now the question came up, why didn’t his defibrillator pick up on this slow VT and treat it accordingly?It could have been either of the two reasons 1) the defibrillator was not reading the signal 2) it could not diagnose it. But we saw that there were signal readings on the marker channels which implies that the lack of diagnoses was the issue. Just looking squarely at the VT reading, it is about 90 beats per minute. That VT is under the VT cut-off and not just Biotronik but no other implanted defibrillator device can diagnose such a reading. While 90 beats per minute is not as dangerous as say 180 beats per minute, it is terrifying for a patient with just 19% pumping capacity. A minor activity such as a flight up the stairs, during such an episode, can lead to worsening of the situation.TreatmentThe patient was called into the clinic and treated with aggressive Anti-Tachycardia Pacing (ATP). To explain simply, an ATP is a form of localized stimulated pacing used to treat tachyarrhythmia, by pacing faster than the arrhythmia. It can be executed using an implanted device. How does it work? Well, if the VT is at 120 beats per minute, we pace the ventricles at 140 beats per minute, aiming to break the re-entry cycle. In the case of this patient, we manually paced him at 110 beats per minute and broke the cycle. Post this event, and owing to repeated events that were reported, we admitted him and gave him a VT ablation using 3D mapping. It has now been three years and the patient has been free of any episodes.Food for ThoughtAs we come to the end of this post, I would like to leave you with food for thought. We spoke about virtual clinics. But who exactly is monitoring the remote readings at such clinics? The case discussed above was a yellow alert event for the device, despite it being of an urgent nature. Typically, these messages would arrive at the virtual clinics only the next day. We were successful in this case because we could manually diagnose this, in a timely manner by knowing our patient and carefully analyzing two different reports and making the connection. Now imagine, usually, there are very well educated nurses manning these “virtual clinics”. However, are they equipped enough to make advanced diagnoses like we just did? That is something, we need to think about.Here at EPme.me we love feedback; our aim is to help you learn so please do get in touch with ideas for sessions you’d like to see. Whether you work in electrophysiology, devices, both or neither, we want to hear from you. Follow our YouTube channel to keep up to date with leading cardiac electrophysiology from around the world. Sign up for our newsletter to receive our free ECG cheatsheet — you’ll wonder how you did without it.COMING UP: Next few weeks, we’re gonna be talking about using devices in arrhythmia diagnosis. Some really interesting case studies from devices, to explore further the effects and use of devices in EP.Thank you so much!Website: https://epme.me/Instagram: http://instagram.com/cardiac_electrophysiologyTwitter: https://twitter.com/EPmedotmeFacebook: https://www.facebook.com/EPme.me/Pinterest: https://www.pinterest.com/epmedotme/YouTube channel:https://www.youtube.com/channel/UCism4RgECx2HYcn4x_IWhbA?sub_confirmation=1

Video version https://youtu.be/26Fai7FQWG8In my previous post, I looked a little at the history of medicine — starting in medieval times, when medicine began to be the remit of scholars and we saw the nascent emergence of evidence-based practice. Compare that with early surgery, purely physical procedures performed often by barbers and butchers… anyone with a big knife, really. As medics learned more about the structures and functions within the body, surgery and medicine became more closely aligned, eventually enabling specialization within disciplines based on the systems of the body. Now surgery and medicine are distinct but allied parts of the same profession, and nowhere is there more crossover than in cardiac electrophysiology.I explored some of the pros and cons of the increasingly specialized and sub-specialized — sometimes sub-sub-specialized — nature of medicine in general, and cardiology, electrophysiology, and devices in particular.Now let’s look at some of the benefits of professional specialization into electrophysiology: starting with the ever-growing array of implantable devices we have to help us diagnose and manage arrhythmias, starting with Implantable Loop Recorders — ILRs.ILRs are devices implanted under the skin which recognize and record heart rhythms. The implantation of an ILR is a quick, minimally invasive, almost painless and very safe procedure, with a tiny incision usually done as a day case and with only local anesthetic. It can be done in aseptic conditions in procedure rooms or even at the patient’s bedside.Here we have the Biotronik Biomonitor 2; the Abbott’s (St. Jude) Confirm Rx; and the Medtronic Reveal LINQ. They’re all very small so once they’re implanted the patient shouldn’t have any discomfort or even much awareness of them. The insertion site heals as quickly as any other small superficial wound, with minimal, usually barely visible scarring.So, when do we decide to implant an ILR?When someone comes into your clinic with symptoms that could be related to a heart rhythm disorder, such as palpitations, pre-syncope or syncope, the first thing you’ll do is get a 12-lead ECG. A 12-lead can give us a lot of information about the electrical conduction system of the heart, and there may be underlying problems that a 12-lead shows clearly. The problem is, an ECG taken in the clinic is only a snapshot of that moment in time.What we often need is to have our patient attached to a monitor for a longer period of time. We want to see our patients’ heart rhythm when they have the symptoms they’re reporting. It might be that they only get the symptoms when they’re up and about, so having a heart monitor that allows the patient to get on with their normal life is ideal. Sometimes a patient’s symptoms are serious enough or worrying enough that they’ll need to be admitted to hospital for monitoring, but it’s clearly better, both for the patient and for the allocation of clinical resources, if they can go home while they’re monitored.The next step, then, is a Holter monitor: a 3-lead or 12-lead ECG attached externally that can monitor the patient for up to 72 hours. Some Holter monitors have a button that the patient can press when they have symptoms, or it can be useful to ask your patient to keep a diary of their activities and symptoms.What, then, if your patient comes back into the clinic, has a 72-hour recording of their heart behaving perfectly normally, and no symptoms throughout the recording period? What if they have problematic, even potentially harmful symptoms which sound convincingly like a heart rhythm disturbance, but which only happen, say, every few months? We can’t dismiss a convincingly cardiac-sounding syncope in a patient who’s likely to go home, fall down and break a hip just because we haven’t YET got evidence of their arrhythmia. So, we need to monitor them for longer.Enter “The ILR”.Implantable Loop Recorders can monitor your patient for up to three years from insertion (and they’re improving all the time). They can detect a wide variety of arrhythmias, fast, slow, regular, irregular, regularly irregular, and pauses. You can set specific parameters according to the needs of your patient — useful when one patient has a comfortable resting heart rate of 47bpm, and another patient hits the floor when they drop below 60bpm.The ILR automatically detects and records heart rhythm disturbances, and transmits information and alerts through wireless technology ( Abbott(St. Jude), Biotronik, or the Medtronic). The information transmitted and stored is secure and compliant with international and local data privacy legislation. The ILR transmits information using a wireless device usually kept at the patient’s home; this device also allows patients to report symptomatic episodes. This can be incredibly useful, allowing the team analyzing the data to match symptoms to heart rhythm disturbances and work out the root cause of the problem.ILRs are purely diagnostic devices: they record but they don’t treat arrhythmias. Once we’ve worked out the exact cause of the patient’s symptoms we may have a few treatment options, so let’s look at some case studies.Case Study 1:Here’s a report received from a Abbott (St. Jude) Confirm Rx device.We have a single ECG lead, so we can start to have a closer look and analyze the rhythm. Firstly, we can see P waves. We’re only looking at a single lead, so we’re not going to worry about whether our complexes are positive or negative. Where we can see P waves we can also see that they’re closely followed by QRS complexes and that the QRS complexes are nice and narrow. We can see a T wave after the QRS, so we’ve got a good idea of the heart rhythm and can work out intervals within the complexes.In this report, the device has identified this as an episode of bradycardia. At 49bpm, it’s on the edge of normal limits — this is where we need to think about what the patient was doing at the time. If they were climbing a flight of stairs, their heart rate didn’t increase to meet demand, and they felt dizzy, then we’ve got an answer. If, on the other hand, they’re asleep or resting, and if they were asymptomatic while their heart rate was arguably slightly slow, then maybe we can call that normal for this patient, and we can re-programme the monitor to only alert us of bradycardia at less than, for instance, 45bpm. This is where it’s really useful to be able to find out how the patient felt at the time.We can also see from this report that it is basing its rate on ventricular sensed beats — VS — and it also tells us the number of milliseconds between each beat. We can use this to judge pauses and to work out the patient’s heart rate more accurately, and this is especially useful in irregular heart rates. There are a thousand milliseconds in a second, so a rate of 1000 milliseconds is one beat per second or a heart rate of 60bpm. Our patient has an RR interval — the gap between one R wave and the next — of 1074 milliseconds. So, just slightly less than 60bpm. A little further on it records an 1102 millisecond RR interval — so we’re on our way down towards around 52–54bpm.So, is it bradycardia, or is it normal sinus rhythm? Well, this case is a good reminder that everybody’s different, and all we can say, without associated symptoms, is that it seems to be normal for this patient.Case Study 2:Our next case is a recording from a Medtronic Reveal LINQ device. There are a few differences in the interface of different devices, but they all give us the same information. We have our ECG rhythm strip, we can see that it’s labeled VS, for ventricular sensed events, and we can see the RR interval in milliseconds.So what are we looking at here? It’s not bradycardia, although there are some RR intervals of 1790 milliseconds, and it’s not tachycardia, although there are some RR intervals of only 570 milliseconds. The patient actually marked this as a symptomatic episode, so we need to know what’s going on.Firstly, is this an atrial originating rhythm? The discerning eye might spot a P wave before each NARROW QRS, so we know this is an atrial based beat. It has a P wave, it’s a nice narrow QRS complex, it’s following the right pathways in the heart’s conduction system. On this slide, we start off with 3 narrow QRS complexes, with associated P waves and, although a little slow, they’re regular. However, after our third normal QRS complex, we have an early beat. This has a much wider morphology than our previous QRS and is followed by what we call a compensatory pause. This means that the next normal-looking P-wave driven QRS complex falls in about where it would if there’d been another normal beat preceding it, instead of this bizarre early complex. Then we have the same pattern repeated, a narrow complex beat followed by an early broad complex beat and then a compensatory pause. We call this bigeminy — ‘two twins’.Every part of the conduction system in the heart, even down to every cell, has the ability to initiate a heartbeat. The heart works best when the beats originate from the SA node, at the top of the conduction system, and travel through the normal pathways: the AV node, bundle of His, the bundle branches and the Purkinje fibers and through every cell of the heart muscle. These pathways give us a synchronized, coordinated heartbeat, with everything happening at exactly the right time. As we work our way down through the conduction system, we find that every part has its own intrinsic rhythm that will kick in as a safeguard if there’s no signal from above. More on this in another episode!Why do we think this patient has bigeminy? We know that the patient’s normal QRS complexes are narrow, and the premature complexes are wide, taking up almost 200 milliseconds, and so we might assume that the early beat originates from the ventricles. It’s not following the normal conduction pathways, it’s less synchronized than this patient’s normal sino-atrial beat, so we get a broader QRS. All the premature beats have the same shape, the same morphology, and so we know that they originate in the same place in the heart. We can get an idea of where the premature beat originated by the shape of the QRS complex, however, to locate exactly where the originating focus of these beats, is if we catch these beats on a full 12-lead ECG. And if we can pinpoint it then we can ablate it — knock out this tiny problem area and hopefully solve the problem completely.Actually, you’ll notice from this ECG strip that the patient has 8 of these bigeminal beats, and then reverts into a sinus rhythm. Although we tend to assume that a broad complex beat is a ventricular premature beat/complex (VPB/VPC), it’s important to remember that you can get also get broad complex beats with an atrial focus which largely follows normal conduction pathways but with some partial conduction disorder. We call this an atrial beat with aberrancy — it can occur when an early beat comes before the heart has completed its refractory period, and so one of the bundle branches is at a more excitable phase than the other. This causes asynchronicity between the bundle branches and a broad complex on the ECG.Whether these are ventricular beats or aberrant atrial beats, we know that our patient had symptoms when this occurred, so we need to get a 12-lead ECG and work out our treatment options, which may be medication or further EP studies with possible ablation.Case Study 3:Next, we have a case study of a patient with who had recurrent syncopal episodes, in whom we fitted a Medtronic Reveal device. You can see that the device has flagged up a long pause at 5 am. The patient didn’t report symptoms at this time, but we can probably assume that he was asleep, because we know that had he been awake with a pause of this length he would certainly have known about it. The ILR shows us a few seconds before the event so that we can see some regular beats with slightly increasing intervals, and then complete standstill. The report even tells us that the recording was suspended for 10 seconds while it wasn’t receiving any signal from the heart.So this is a long pause, very long, and then — at last! — a beat… and then another pause, and back to its normal rhythm.Phew! So here we have a diagnostic report, we know why the patient has been fainting, and we know that we want to put a pacemaker in him. He had no P waves during his pause, so we can’t call it any kind of AV block, we can’t see any activity at all during his pauses. Of course, we called this patient in for a pacemaker, had him sitting happily in the waiting room pre-procedure, when…This happened! The patient, of course, fainted in the waiting room. We can see on his ILR report that he was having pauses of increasing length, leading to two separate fainting episodes just while he was waiting for his procedure. The patient was very symptomatic and very keen to get his pacemaker! I can’t stress enough how essential the ILR was in diagnosing and ensuring timely treatment of these profound, potentially life-threatening pauses.Case Study 4:Our last case study is of a 46-year-old male patient who was referred to us for repeated syncope and pre-syncope events. He’s had an echocardiogram, a 12-lead ECG, a 24 hour Holter monitor, and hadn’t identified any cause for his fainting. We sent him for some fairly invasive catheter EP studies, which were also normal. Without a clear cardiac cause, we referred him to a neurologist, who also declared the patient to be normal! But his symptoms continued, so we decided on an ILR.Have a look at this patient’s Medtronic Reveal Report. As well as the ECG, it can show us graphs of heart rate and rhythm. We can see just from the graph that this patient’s heart rate is all over the place: 60bpm, 150bpm, a completely irregular ventricular rate.You can also see on the ECG that we have a run of this irregular, fast rhythm, then a three-second pause, and then the heart has reverted into sinus rhythm, at a normal rate. So what was this fast, irregular, narrow complex rhythm? We can’t see P waves, so we know that the atria aren’t contracting in an organized fashion. We can see that it’s narrow complex, so it’s not VT, and that the patient comes out of it themselves (and had a pulse!) so it’s not VF. So it’s fast, with no P waves, irregularly irregular, and not terrifying? It’s AF. It’s the most common cardiac arrhythmia, and it always needs some form of treatment, whether we can control the rhythm or rate because it can cause all kinds of problems — most notably an increased risk of stroke. This patient spontaneously reverted to sinus rhythm which is great, so we can say he’s having paroxysmal AF, during which he’s symptomatic.So how do we treat this patient? Well, he had a little pause… should we put a pacemaker in him? Or should we try EP studies again, knowing now that he has episodes of AF, and ablate the root cause? Or should we medically manage his AF with a lifetime of anti-arrhythmic drugs, beta-blockers, and even blood-thinners if we can’t keep him in NSR?We went with the AF ablation, and we left the ILR in for the duration of its battery life so that we can see if we’ve cured the AF.And…We have! He’s had no episodes of AF, none of the symptoms he used to have, and he doesn’t need any permanently implanted devices or lifelong medication for his heart.These are some of the great successes of ILR technology, which can be an incredibly useful diagnostic tool. In the next episode, we’re going to expand on implantable devices and look at some devices that don’t only record and monitor but can also treat arrhythmias — implantable cardioverter-defibrillators (ICDs).Here at EPme.me we love feedback; our aim is to help you learn so please do get in touch with ideas for sessions you’d like to see. Whether you work in electrophysiology, devices, both or neither, we want to hear from you. Follow our YouTube channel to keep up to date with leading cardiac electrophysiology from around the world. Sign up for our newsletter to receive our free ECG cheatsheet — you’ll wonder how you did without it.COMING UP: Next few weeks, we’re gonna be talking about using devices in arrhythmia diagnosis. Some really interesting case studies from devices, to explore further the effects and use of devices in EP.Thank you so much!Website: https://epme.me/Instagram: http://instagram.com/cardiac_electrophysiologyTwitter: https://twitter.com/EPmedotmeFacebook: https://www.facebook.com/EPme.me/Pinterest: https://www.pinterest.com/epmedotme/YouTube channel:https://www.youtube.com/channel/UCism4RgECx2HYcn4x_IWhbA?sub_confirmation=1

This week, your hosts Steve Lowry and Yvonne Godfrey interview Randi McGinn of McGinn, Montoya, Love & Curry. P.A. (MMLC) - www.mcginnlaw.com   Remember to rate and review GTP in iTunes: Click Here To Rate and Review   Case Details:   Sowards v. Biotronik, wrongful implant of a pacemaker in exchange for kickbacks.   Read More Here   Click Here to Read/Download the Complete Trial Documents (Plaintiff's Opening, Plaintiff's Closing, Special Verdict Form Compensatory/Punitive Damages)   Guest Bio: Interesting Stuff Randi McGinn is the author of “Changing Laws, Saving Lives: How to Take on Corporate Giants and Win,” available through Trial Guides at: http://www.trialguides.com/book/changing-laws-saving-lives/ She is one of the country's leading trial lawyers, having tried over 130 cases, including those of women survivors of sexual assault, harassment, and retaliation. The first woman president of the Inner Circle (100 best trial lawyers in the US), she is known for her creativity in the courtroom and use of demonstrative evidence to visualize opening, direct, cross-examination and closing argument. She has destroyed adverse witnesses by leaving a pretentious Beverly Hills doctor standing in front of the jury covered with post-its and clutching a grapefruit to his chest, by grilling a government snitch until he threw up and by exposing the fact that a world-renowned polygraph expert had been polygraphing his own sperm cells in the dead of night. In a particularly hard-won police shooting case, the local SWAT cops once put her face on their Christmas pinata and took turns whacking it with a big stick. She recently was appointed as a special prosecutor and tried the first murder prosecution in over 50 years of an Albuquerque police officer for an on the job shooting. Started her career by giving birth to daughter Heather, now age 38, the day before the 3-day bar examination. Boring Stuff Senior partner with her three women partners in a law firm in Albuquerque, New Mexico; double listed in criminal and civil litigation in Best Lawyers in America; International Academy of Trial Lawyers fellow; past AAJ Governor; past president of the New Mexico Trial Lawyers' Association; NACDL board member, NITA-NCDC-UNM adjunct instructor. Randi's Full Bio   Show Sponsors   Legal Technology Services - LTSatlanta.com   Forge Consulting - ForgeConsulting.com   Harris, Lowry, and Manton - hlmlawfirm.com   Free Resources: Stages Of A Jury Trial - Part 1 Stages Of A Jury Trial - Part 2  

Roberto, General Manager América Latina da Biotronik, é movido por desafios, ele mesmo cita que 30 anos de indústria farmacêutica não mudaram nada sua paixão por ela. Transparente e justo conversamos sobre como fazer diferença na vida de pessoas e no verdadeiro significado de legado.Sua inspiração atual vem do ex-monge e best-seller Jay Shetty que fala sobre significado, propósito e valores em seu canal do YouTube.Nesse bate-papo, descontraído e cheio de energia, Alvarenga enaltece a transformação e como lida com diferentes culturas e pessoas.Acesse Via Oral ou pelo Instagram @viaoral#viaoral

In this episode of the Cameron-Brooks Podcast, Rudy Chavez, former AF F-15 Pilot and now a Sales Representative with BIOTRONIK, the fastest growing Cardiac Rhythm Management company in the US, tells his story of success. In the episode, Rudy and I talk about: Self-motivation Building trusting relationships How he focuses on self-development The best advice he received, "Give 'em he(ck)." The podcast starts out a little slow, due to my interviewing skills, but improves as it progresses and is full of great advice.  Stick with it.

In this episode of the Cameron-Brooks Podcast, Rudy Chavez, former AF F-15 Pilot and now a Sales Representative with BIOTRONIK, the fastest growing Cardiac Rhythm Management company in the US, tells his story of success. In the episode, Rudy and I talk about: Self-motivation Building trusting relationships How he focuses on self-development The best advice he received, "Give 'em he(ck)." The podcast starts out a little slow, due to my interviewing skills, but improves as it progresses and is full of great advice.  Stick with it.